1. Scrip
  2. >>Business

Pfizer Buys Anacor With Blockbuster Ambitions For Crisaborole

 
• By Jessica Merrill

Pfizer Inc. has made its first M&A move since the planned mega-deal with Allergan PLC collapsed. The big pharma announced May 16 that it will buy Anacor Pharmaceuticals Inc. for $99.25 per share in cash, or approximately $5.2bn.

The deal is a bolt-on acquisition by Pfizer’s standards, nothing like the $160bn merger Pfizer had been planning with Allergan that was thwarted in April by the US treasury. (Also see "Pfizer-Allergan Merger: The End Is Nigh " - Scrip, 6 April, 2016.) But it is in line with the way management has been guiding investors to think about Pfizer’s M&A strategy, mainly that the company is interested in on-market or late-stage assets that will help drive growth in the innovative side of the business.

Anacor owns a non-steroidal topical phosphodiesterase-4 (PDE-4 inhibitor), crisaborole, that is currently under review by FDA for the treatment of...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

In Brief: BioVersys And Shionogi Align In Non-Tuberculous Mycobacteria R&D

 
• By Joseph Haas

Deal Snapshot: Having recently raised an $89m IPO, BioVersys is partnering on and optioning rights to a preclinical NTM development program with Shionogi.

BerGenBio Plumps For Oncoinvent From Long List Of 50 Suitors

 
• By Kevin Grogan

The merger with a fellow Norwegian biotech comes a few months after its lead asset, bemcentinib, bit the dust.

Global Pharma Interest In Korea Undeterred Despite Political Roller Coaster

 
• By Jung Won Shin

Despite recent political turmoil, outside investor and corporate interest in South Korean biopharma innovation appears robust or even increasing.

Protagonist Hopes To Come From Behind In Obesity With Oral Triple Agonist

 
• By Jessica Merrill

The company announced plans to move an oral GLP-1/GIP/GCG receptor agonist peptide into clinical development for obesity in 2026.

More from Scrip

In Brief: BioVersys And Shionogi Align In Non-Tuberculous Mycobacteria R&D

 
• By Joseph Haas

Deal Snapshot: Having recently raised an $89m IPO, BioVersys is partnering on and optioning rights to a preclinical NTM development program with Shionogi.

In Brief: Atai-Beckley Deal Marches On After Phase II Psychedelic Win

 
• By Manas Mishra

The psychedelic therapy firms pass a key condition for their planned merger after the antidepressant BPL-003 meets the main endpoints of a Phase IIb trial.

BerGenBio Plumps For Oncoinvent From Long List Of 50 Suitors

 
• By Kevin Grogan

The merger with a fellow Norwegian biotech comes a few months after its lead asset, bemcentinib, bit the dust.